OptiKira Receives Significant Grant from ALS Association
CLEVELAND, OH – February 9, 2017
OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig’s disease). The company’s technology prevents progressive cell death and is being developed for a range of degenerative diseases including ALS, retinitis pigmentosa and diabetes. OptiKira is based on the discoveries of Harrington Scholars from UCSF and technology licensed from UCSF and the University of Washington.